PROCEPT BioRobotics Corporation (PRCT)
NASDAQ • Healthcare
Last close at September 11, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, PROCEPT BioRobotics Corporation currently loses $28.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 3
in 51 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
PROCEPT BioRobotics’ revenue topped consensus in the second fiscal quarter of 2026, even as EPS trailed, in results reported August 4, 2026. Revenue rose 19.3% to roughly $94.5 million, up from $79.2 million a year ago, and came in at $94.5 million versus a $92.8 million estimate, +1.9%. Gross profit was about $62.4 million, with gross margin at 66.0%, while operating income was -$27.4 million and operating margin stood at -29.0%. Net income was -$26.9 million, down 37.2% from -$19.6 million a year ago, and EPS was -$0.47 versus -$0.35 a year ago; on the consensus tape, EPS of -$0.47 trailed the -$0.46 estimate (difference -$0.01). The quarter also included negative operating cash flow of roughly $57.4 million. For the next period, consensus calls for EPS of -$0.39 on revenue of $101.1 million.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) makes urology-focused medical devices built around robotic treatment for benign prostatic hyperplasia, centered on the AquaBeam Robotic System and Aquablation therapy. The company generated $308.1 million of revenue in FY2025. Its business sits in healthcare, where it develops and sells surgical technology for minimally invasive procedures.
Today's Snapshot
PRCT closed 1.5% above yesterday's close, while its sector was flat. Shareholders’ lawyers pursued a securities-fraud class action against PROCEPT over alleged undisclosed inventory issues.
Trading Volume
Above 10d avg 1.1M
1.4M
vs S&P 500 Today
Outperforming Market
+0.61%
Updated: September 11, 2026 at 20:07 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$20.99 - $25.81Sell
- RSI (14)46.78Neutral
- Stochastic %K (14, 3, 3)17.21Buy
- MACD Level (12, 26)0.07Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.